Literature DB >> 17474269

HFE mutation H63D predicts risk of iron over load in thalassemia intermedia irrespective of blood transfusions.

Vineeta Sharma1, Inusha Panigrahi, Pankhi Dutta, Seema Tyagi, Ved Prakash Choudhry, Renu Saxena.   

Abstract

Iron overload is a well-documented complication in thalassemia intermedia. Moreover, it is seen that the number of blood transfusions received does not correlate with the degree of overload. Since, HFE gene is associated with iron overload; the present study was conducted in an attempt to evaluate its role in thalassemia intermedia. The subjects were consecutive thalassemia intermedia cases attending the Hematology outpatient clinic. Controls were healthy hospital staff with negative family history of hemolytic anemia or liver disease. The molecular analysis for HFE mutations H63D and C282Y were done with primers described earlier. ELISA was used to measure serum ferritin. Sixty-three patients of thalassemia intermedia including 48 beta-homozygous/heterozygous thalassemia intermedia and 15 HbE-beta-thalassemia were studied. Six (12.5%) of the former and two (13.3%) of the latter were heterozygous for H63D; one of which, a 51-year old male also had clinical features of hemochromatosis. In healthy controls, prevalence of H63D heterozygosity was 7.5% (6/80). An interesting feature observed was that though the age and transfusions taken were similar in both groups, the serum ferritin greater than 500 ng/dl were observed in all patients (100%) with HFE mutation whereas it was seen in 12/42 (28.6 %) of patients without the mutation (p = 0.002). Thus, it is concluded that thalassemia intermedia patients with co-existent HFE mutation have a higher likelihood of developing iron overload and may require early iron chelation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17474269

Source DB:  PubMed          Journal:  Indian J Pathol Microbiol        ISSN: 0377-4929            Impact factor:   0.740


  7 in total

1.  Serum ferritin in thalassemia intermedia.

Authors:  Ravi Shah; Amita Trehan; Reena Das; R K Marwaha
Journal:  Indian J Hematol Blood Transfus       Date:  2013-06-06       Impact factor: 0.900

2.  Serum Hepcidin as a Diagnostic Marker of Severe Iron Overload in Beta-thalassemia Major.

Authors:  Ahmed Maher Kaddah; Amina Abdel-Salam; Marwa Salah Farhan; Reham Ragab
Journal:  Indian J Pediatr       Date:  2017-06-10       Impact factor: 1.967

3.  Impact of HFE-2 and HAMP Gene Variations on Iron Overload in Pediatric Patients with Non-Transfusion Dependent Thalassemia: A Pilot Study.

Authors:  Niteesh Bharadwaj; Srinivasan Peyam; Prateek Bhatia; Anmol Bhatia; Reena Das; Minu Singh; Deepak Bansal; Amita Trehan; Richa Jain
Journal:  Indian J Hematol Blood Transfus       Date:  2021-05-07       Impact factor: 0.900

4.  HFE Gene Mutations and Iron Status in 100 Healthy Polish Children.

Authors:  Barbara Kaczorowska-Hac; Marcin Luszczyk; Jedrzej Antosiewicz; Wieslaw Ziolkowski; Elzbieta Adamkiewicz-Drozynska; Malgorzata Mysliwiec; Ewa Milosz; Jan J Kaczor
Journal:  J Pediatr Hematol Oncol       Date:  2017-07       Impact factor: 1.289

5.  Serum ferritin levels and irregular use of iron chelators predict liver iron load in patients with major beta thalassemia: a cross-sectional study.

Authors:  Soheila Sobhani; Farzaneh Rahmani; Maryam Rahmani; Marzieh Askari; Farzad Kompani
Journal:  Croat Med J       Date:  2019-10-31       Impact factor: 1.351

6.  Frequency of Hereditary Hemochromatosis (HFE) Gene Mutations in Egyptian Beta Thalassemia Patients and its Relation to Iron Overload.

Authors:  Azza Aboul Enein; Nermine A El Dessouky; Khalda S Mohamed; Shahira K A Botros; Mona F Abd El Gawad; Mona Hamdy; Nehal Dyaa
Journal:  Open Access Maced J Med Sci       Date:  2016-06-01

7.  The Relation between Serum Hepcidin, Ferritin, Hepcidin: Ferritin Ratio, Hydroxyurea and Splenectomy in Children with β-Thalassemia.

Authors:  Nagwa Abdallah Ismail; Sonia Adolf Habib; Ahmed A Talaat; Naglaa Omar Mostafa; Eman A Elghoroury
Journal:  Open Access Maced J Med Sci       Date:  2019-08-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.